Next Article in Journal
Evolution of Epileptiform Activity in Zebrafish by Statistical-Based Integration of Electrophysiology and 2-Photon Ca2+ Imaging
Next Article in Special Issue
The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
Previous Article in Journal
Roles and Functions of ROS and RNS in Cellular Physiology and Pathology
Previous Article in Special Issue
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Open AccessReview

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias

1
Department of Medicine (DIMED), Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy
2
Veneto Institute of Molecular Medicine (VIMM), 35129 Padova, Italy
*
Author to whom correspondence should be addressed.
Cells 2020, 9(3), 768; https://doi.org/10.3390/cells9030768
Received: 13 February 2020 / Revised: 14 March 2020 / Accepted: 19 March 2020 / Published: 21 March 2020
Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuzumab, the effect of anti-CD38 mAbs on NK system is controversial. As a matter of fact, an initial reduction of NK cells number characterizes Daratumumab therapy, limiting the potential role of this subset on myeloma immunotherapy. In this paper we discuss the role of NK cells along with anti-CD38 therapy and their implication in plasma cell dyscrasias, showing that mechanisms triggered by anti-CD38 mAbs ultimately lead to the activation of the immune system against myeloma cell growth. View Full-Text
Keywords: CD38; NK cells; multiple myeloma CD38; NK cells; multiple myeloma
Show Figures

Figure 1

MDPI and ACS Style

Zambello, R.; Barilà, G.; Manni, S.; Piazza, F.; Semenzato, G. NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. Cells 2020, 9, 768.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop